Kiniksa Pharmaceuticals International (KNSA) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 104.5% versus a gain of 4.7%. Over five years, KNSA leads with a +580.9% price change compared with +37.2% for NBIX. Neurocrine Biosciences is the larger company by market cap ($14.58 billion vs $6.08 billion), about 2.4 times the size, while Kiniksa Pharmaceuticals International is growing revenue faster (+60.1% vs +21.4%).
On valuation, Neurocrine Biosciences trades at a lower forward P/E (12.1x vs 48.2x for Kiniksa Pharmaceuticals International). Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus 8.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KNSA | NBIX |
|---|---|---|
| Share price | $77.96 | $143.47 |
| Market cap | $6.08B | $14.58B |
| 1-day change | +1.13% | -1.40% |
| YTD return | +88.99% | +1.16% |
| 1-year return | +104.51% | +4.72% |
| 5-year return | +580.87% | +37.24% |
| P/E ratio (TTM) | 78.75 | 21.04 |
| Forward P/E | 48.20 | 12.08 |
| EPS (TTM) | $0.99 | $6.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $677.56M | $2.86B |
| Revenue growth (YoY) | +60.09% | +21.45% |
| Net income (latest FY) | $59.01M | $478.60M |
| Gross margin | 88.54% | 98.18% |
| Operating margin | 11.40% | 21.64% |
| Net margin | 8.71% | 16.73% |
| 52-week high | $82.94 | $186.12 |
| 52-week low | $35.20 | $122.14 |
| Distance from 52-week high | -6.00% | -22.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +25.71% | +44.48% |
| Average volume | 578.96K | 1.30M |
| Shares outstanding | 48.29M | 101.65M |
| Employees | 366 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neurocrine Biosciences is about 2.4 times larger than Kiniksa Pharmaceuticals International by market value ($14.58B vs $6.08B).
- KNSA has outperformed NBIX by 99.8 percentage points over the past year.
- Kiniksa Pharmaceuticals International trades at a higher earnings multiple (78.7x vs 21.0x trailing P/E).
- Neurocrine Biosciences is more profitable, keeping 16.7 cents of every revenue dollar as net income versus 8.7 cents for Kiniksa Pharmaceuticals International.
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +21.45%).
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
KNSA vs NBIX FAQ
Which is bigger, Kiniksa Pharmaceuticals International or Neurocrine Biosciences?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.58B compared with $6.08B for Kiniksa Pharmaceuticals International (KNSA).
Which stock has performed better over the past year, KNSA or NBIX?
KNSA returned +104.51% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, KNSA or NBIX?
NBIX has the lower trailing P/E at 21.0, versus 78.7 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Kiniksa Pharmaceuticals International and Neurocrine Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Kiniksa Pharmaceuticals International and Biotechnology: Biological Products (No Diagnostic Substances) for Neurocrine Biosciences.